Signals, Powered By EquityPandit
The USFDA has provided its approval to the drug firm Cipla for marketing Entecavir tablets that are used in the treatment of Hepatitis B infection.
Cipla has said in a BSE filing that “it has received final approval for its abbreviated new drug application (ANDA) for Entecavir tablets USP 0.5 mg and 1 mg from the United States Food and Drug Administration (USFDA)”.
It added that “the tablets are indicated for the treatment of chronic Hepatitis B virus infection.”
